Thought Leadership

Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends


Integrating Lab Data Into Your Physician Engagement Strategy: 5 Key Benefits

For manufacturers, successful physician engagement hinges on the ability to prioritize physicians with a high volume of potentially eligible patients—and to interact with those physicians at the ideal moment in time, when they are most receptive to brand messaging. While many pharma companies rely on retrospective claims data to identify

Will Interchangeability Status Truly Move the Needle With Biosimilars?

When it comes to biosimilars, there seem to be far more questions than answers, specifically when it comes to interchangeability. Now that the FDA has granted three biosimilar products “interchangeable” status—with more to come, surely—how will this development affect the biosimilars market? What do pharma manufacturers, payers and physicians need
0 Comments Biosimilars

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Next year’s staggered launch of adalimumab biosimilars will mark one of the largest losses of exclusivity for a pharmaceutical company in U.S. market history. For years, Humira has been the top-selling drug worldwide, raking in more than $20 billion in revenue last year. Manufacturers of reference biologics will be monitoring the impending
0 Comments Biosimilars

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

While the U.S. has been frustratingly slow to embrace biosimilars, the next few years are poised to see a veritable boom in new market entrants. Only six biosimilars were available at the end of 2018. There are now around 40 biosimilars approved in the U.S. across multiple indications. Plus, enrollment in the
0 Comments Biosimilars